TEVA-TRIMEL DS 800 MG
SULFAMETHOXAZOLE : 800 MG TRIMETHOPRIM : 160 MG · DIN 00510645 · TEVA CANADA LIMITED
Health Canada status: DORMANT
What is TEVA-TRIMEL DS?
TEVA-TRIMEL DS 800 MG contains SULFAMETHOXAZOLE : 800 MG TRIMETHOPRIM : 160 MG. It is listed in the Health Canada Drug Product Database under DIN 00510645, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 14-May-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-TRIMEL DS used for?
Infections caused by susceptible organisms: UTIs, acute exacerbations of chronic bronchitis, Pneumocystis jiroveci pneumonitis, cholera (adjunct), and second-line for brucellosis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00510645 |
|---|---|
| Brand name | TEVA-TRIMEL DS |
| Generic / active ingredient | SULFAMETHOXAZOLE : 800 MG TRIMETHOPRIM : 160 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 800 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 14-May-2021 |
How is it administered?
Dosage should be adjusted for renal function. Maintain adequate urinary output. Specific doses for PJP and cholera mentioned. See full monograph for detailed weight-based/infection-specific dosing.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard practice is 15-30°C).
How is it supplied?
Not explicitly detailed in provided text (mentions Tablets, DS Tablets, and Oral Suspension).
Contraindications
Hypersensitivity to trimethoprim or sulfonamides; megaloblastic anemia due to folate deficiency; marked liver damage; blood dyscrasias; marked renal impairment; pregnancy; nursing; infants <2 months.
Warnings and precautions
Fatalities from SJS, TEN, fulminant hepatic necrosis, and blood dyscrasias. Discontinue at first sign of rash. Risk of Clostridium difficile-associated disease (CDAD) and hyperkalemia.
Is SULFAMETHOXAZOLE AND TRIMETHOPRIM in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by AURO PHARMA INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM. 6 of 31 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| SEPTRA INJECTION | 16 MG | SOLUTION | ASPEN PHARMACARE CANADA INC. | MARKETED | DIN 00550086 |
| SULFAMETHOXAZOLE AND TRIMETHOPRIM FOR INJECTION, USP | 16 MG | SOLUTION | AURO PHARMA INC | MARKETED | DIN 02525917 |
| SULFAMETHOXAZOLE AND TRIMETHOPRIM FOR INJECTION, USP | 80 MG | SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02534746 |
| SULFATRIM | 80 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00445274 |
| SULFATRIM DS | 800 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00445282 |
| SULFATRIM PEDIATRIC | 100 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00445266 |
| APO-SULFATRIM ORAL SUSPENSION | 40 MG | SUSPENSION | APOTEX INC | CANCELLED POST MARKET | DIN 00846465 |
| BACTRIM DS ROCHE TAB | 160 MG | TABLET | HOFFMANN-LA ROCHE LIMITED | CANCELLED POST MARKET | DIN 00371823 |
| BACTRIM ROCHE INJ | 80 MG | LIQUID | HOFFMANN-LA ROCHE LIMITED | CANCELLED POST MARKET | DIN 00550078 |
| BACTRIM ROCHE SUSPENSION PAEDIATRIC | 40 MG / 5 ML | SUSPENSION | HOFFMANN-LA ROCHE LIMITED | CANCELLED POST MARKET | DIN 00272485 |
Who else supplies SULFAMETHOXAZOLE AND TRIMETHOPRIM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SULFAMETHOXAZOLE AND TRIMETHOPRIM appears in 19 registered pack listings across 6 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.